Article

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis

2024-01-19

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose:</bold> This study investigates the role and effectiveness of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in oral cancer, focusing on the clinical relevance of EGFR and myeloid cell leukemia-1 (Mcl-1) in head and neck cancers (HNCs). It aims to explore the molecular mechanism of afatinib, a TKI, in treating human oral cancer. <bold>Methods:<...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4760d0f-48d9-5ab3-8c6d-e9fc9d6fbacf
DOI: 10.21203/rs.3.rs-3872267/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axisDOI 10.21203/rs.3.rs-3872267/v1Read

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.Semantic proximity Read

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trialSemantic proximity Read

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity Read

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Semantic proximity Read

Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastomaSemantic proximity Read

[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].Semantic proximity Read

Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach.Semantic proximity Read

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.Semantic proximity Read

Anlotininb as a Promising Inhibitor on Tumor Growth of Oral Squamous Cell Carcinoma Through Cell Apoptosis and Mitotic CatastropheSemantic proximity Read

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.Semantic proximity Read

Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacySemantic proximity Read

Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.Semantic proximity Read